Rational approaches to drug pricing and insurance coverage

Americans rank lowering prescription drug prices as a top policy priority. We focus on developing rational approaches to drug pricing and reimbursement that sustain innovation while ensuring patient access and affordability.
Learn About Our Work

Featured News

See All News
Bloomberg Opinion 07/16/2020

Before Spending Billions, U.S. Hospitals Need to Study Remdesivir Further

As COVID-19 continually evolves and new therapies are approved and administered individually and in combination, the best way to apply scientific principle is to continue to test each treatment separately and together, beginning with Remdesivir.
Read Article
The Challenge

With new drugs entering the market at record-breaking prices and costly gene and cell therapies in the pipeline, access and affordability are pressing concerns. But the current healthcare system allows for, and even encourages, the rise.

Explore the Challenge
Who We Are

We are a non-partisan, independent research group with extensive interdisciplinary expertise in medicine, policy, economics, finance, and social science tackling this drug pricing challenge.

Learn More About Us

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.
Relentless Health Value 12/10/2020
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Understanding the Rewards of Successful Drug Development: Thinking Inside the…
The ability to charge high prices is only one component of a complex system of risks and rewards that underlies pharmaceutical innovation
NEJM 01/30/2020
Medicare Negotiation: A "Too Little" or "Too Late" Framework for…
Recent draft pieces of legislation and regulation take aim at the rising cost of drugs, targeting drugs that claim the largest share of the health care budget and that face limited competition from generics or biosimilars.
NEJM 11/28/2019
Fact Check: Time to Market for New Drugs in U.S.…
Drug prices in the U.S. are highest among developed countries, effectively setting the upper bound for reference prices elsewhere.
Drug Pricing Lab 10/11/2019
Health Affairs: Abandon Biosimilars as Biologics are Natural Monopolies
Biosimilars will not effectively lower the price of biologic drugs after the period of market exclusivity.
HA Blog 04/15/2019
Impact of President's Budget and Point of Sale Rebate Proposal…
Milliman analyzes the impact of the proposed rule to implement point of sale rebates in Medicare Part D.
Drug Pricing Lab 03/08/2019
List Price, Net Price, and the Rebate Caught in the…
Pharmacy benefit managers (PBMs), such as Express Scripts, CVS Caremark, and Optum Rx, are some of the larger companies that administer the Medicare Part D prescription drug benefit.
JAMA Viewpoint 03/06/2019
Overview of Original Subscription Model and Features of LA and…
An overview of the original subscription-based Netflix model proposed and the proposals put forth by Louisiana and Washington.
Drug Pricing Lab 01/29/2019
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
JCO 02/19/2013

Learn how drug pricing works

Certain aspects of the payment and reimbursement processes in the U.S. distort incentives and negatively influence drug prices. Learn how through our tutorials.

Explore Our Tutorials

Our Tools

See All Tools

Drug Abacus

How would you price a drug? This interactive tool takes more than 50 cancer drugs and lets you compare the company's price to one based on "value."

Use the Tool

Policy Tracker

The DPL Policy Tracker keeps tabs on federal policy proposals to address US drug pricing issues.

Use the Tool

Louisiana Budget Allocator

There is no such thing as a free drug. The Louisiana Budget Allocator analyzes the budget impacts of paying for Hepatitis C treatment for Louisiana's Medicaid and uninsured recipients.

Use the Tool
Newsletter

Stay up to date on our work and news